Acute Ischemic Stroke
Conditions
Keywords
Acute ischemic stroke, heart, Reperfusion Therapy
Brief summary
Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy. This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.
Detailed description
There is growing evidence pointing to close interactions between acute ischemic stroke (AIS) and heart diseases. Heart diseases may lead to AIS (heart-to-brain interactions), with many cardiac conditions have been proposed as potential sources of cerebral embolism, and studies have also shown that AIS can induce cardiac injury (brain-to-heart interactions), namely Stroke-Heart Syndrome. In addition, due to the commonly shared risk factors, AIS patients had a significantly higher frequency of coexisting prior known or unknown coronary heart disease (brain-and-heart interactions). These heart problems not only add complexity to the etiological diagnosis but also account for a great proportionate mortality in AIS patients with reperfusion therapy, which is the most effective treatment method for AIS. The interconnected and coexisting properties of AIS and heart diseases requires a comprehensive scheme to evaluate, prevent, and treat patients. Heart Evaluation of Acute ischemic stroke with Reperfusion Therapy (HEART) is a single-center observational registry evaluating the heart of patients hospitalized for acute ischemic stroke with reperfusion therapy. This registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies. The clinical, laboratory and imaging information will be collected at the baseline. During an estimated 3-year follow-up, the diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.
Interventions
observational only- no intervention
Sponsors
Soochow University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent by patient 2. Age ≥ 18 years 3. Acute ischemic stroke (with matching brain lesion on MR imaging) 4. Enrolment within 24 h after onset of stroke-related symptoms.
Exclusion criteria
1. Pregnancy and / or breast-feeding. 2. Participation in an interventional study. 3. Patients refuse to participate in the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Major Adverse Cardiovascular Events | 1 year | cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Ischemic Stroke | 1 year | fatal and nonfatal ischemic stroke. |
| Rate of Acute Coronary Syndrome | 1 year | fatal and nonfatal myocardial infarction and unstable angina |
| Rate of Cardiovascular Mortality | 1 year | any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death |
| Functional Outcome | 90 days | Percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled. |
| Time to First Major Adverse Cardiovascular Event | 3 years | from the date of enrollment until the date of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina, whichever comes first, assessed up to 3 years |
| Time to First Ischemic Stroke | 3 years | from the date of enrollment until the date of first documented ischemic stroke, assessed up to 3 years |
| Rate of Major Adverse Cardiovascular Events | 90 days | ardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina |
Countries
China
Contacts
Primary ContactJianqiang Ni, MD, PhD
Outcome results
None listed